During the three months ended July 4, 2026, the Company initiated an Eyeglass World lab optimization initiative designed to optimize certain in-store laboratory functions by transitioning in-store lab surfacing activities to the Company's central laboratory operations. As a result of this transition, the Company eliminated certain positions within the affected in-store laboratories, impaired certain laboratory equipment and wrote off inventory that is no longer expected to be utilized in operations.

The Company expects substantially all activities under the plan to be completed within one year and does not expect to incur any material additional costs. Total costs associated with the plan are expected to be approximately $3.0 million to

$4.0 million, consisting primarily of non-cash equipment impairment charges, inventory write-offs, and employee termination benefits. The Company will continue to evaluate the impact of the transition and may incur additional costs as the plan is executed.

The following table presents the charges recognized related to the plan and their classification within the Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended July 4, 2026.

In thousands

Income Statement Classification

Three and Six Months Ended July 4, 2026

Employee termination benefits

Costs of services and plans

131

Asset impairment

2,506

Inventory write-off

Costs of products applicable to revenue

206

Other Costs

Selling, general, and administrative expenses

233

Total restructuring charges

3,076

As of July 4, 2026, the full amount of $0.1 million of the restructuring-related employee termination benefits had been accrued and is recorded in Other payables and accrued expenses within the Condensed Consolidated Balance Sheets. These charges were recognized in accordance with FASB guidance on accounting for costs associated with exit or disposal activities. All expenses were recognized in the Corporate and Other category.